NYSE:LCI - Lannett Stock Price, Price Target & More Sign in or create an account to add this stock to your watchlist. Get Started $13.15 +0.60 (+4.78 %) (As of 07/18/2018 01:10 AM ET)Previous Close$12.55Today's Range$12.60 - $13.3552-Week Range$12.15 - $30.35Volume586,200 shsAverage Volume705,374 shsMarket Capitalization$516.99 millionP/E Ratio4.60Dividend YieldN/ABeta2.57 Company ProfileFinancialsAnalyst RatingsEarnings HistoryInsider TradesHeadlinesOptions ChainSEC FilingsSocial MediaChart Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Lannett Company, Inc. develops, manufactures, packages, markets, and distributes generic versions of brand pharmaceutical products in the United States. The company offers solid oral, extended release, topical, nasal, and oral solution finished dosage forms of drugs that address a range of therapeutic areas, as well as ophthalmic, patch, foam, buccal, sublingual, soft gel, and injectable dosages. It also provides its products for various medical indications comprising glaucoma, cholesterol, muscle spasm, migraine, pain management, cardiovascular, antipsychosis, gastrointestinal, urinary, bronchospasms, respiratory, gallstone, congestive heart failure, thyroid deficiency, central nervous system, and gout. In addition, the company manufactures active pharmaceutical ingredients; and markets its products under the Diamox, Lipitor, Lioresal, Fioricet, Fiorinal, Lanoxin, Prolixin, MiraLAX, Imdur, Levoxyl/Synthroid, Metadate CD, Concerta, Procardia, Prilosec, Ditropan, Protonix, Imitrex, Brethine, Tussionex, and Actigall brands. Further, it sells pharmaceutical products to generic pharmaceutical distributors, drug wholesalers, chain drug retailers, private label distributors, mail-order pharmacies, other pharmaceutical manufacturers, managed care organizations, hospital buying groups, governmental entities, and health maintenance organizations. The company has supply and development agreements with JSP, Summit Bioscience LLC, HEC Pharm Group, and Pharma Pass II LLC. Lannett Company, Inc. was founded in 1942 and is based in Philadelphia, Pennsylvania. Receive LCI News and Ratings via Email Sign-up to receive the latest news and ratings for LCI and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryPharmaceuticals SectorMedical SymbolNYSE:LCI CUSIP51601210 Webwww.lannett.com Phone215-333-9000 Debt Debt-to-Equity Ratio1.29 Current Ratio2.56 Quick Ratio1.91 Price-To-Earnings Trailing P/E Ratio4.60 Forward P/E Ratio4.21 P/E GrowthN/A Sales & Book Value Annual Sales$633.34 million Price / Sales0.79 Cash Flow$4.2419 per share Price / Cash3.10 Book Value$15.07 per share Price / Book0.87 Profitability EPS (Most Recent Fiscal Year)$2.86 Net Income$-580,000.00 Net Margins7.01% Return on Equity18.64% Return on Assets6.73% Miscellaneous Employees1,126 Outstanding Shares38,010,000Market Cap$516.99 Lannett (NYSE:LCI) Frequently Asked Questions What is Lannett's stock symbol? Lannett trades on the New York Stock Exchange (NYSE) under the ticker symbol "LCI." How were Lannett's earnings last quarter? Lannett Company, Inc. (NYSE:LCI) released its quarterly earnings data on Monday, May, 7th. The company reported $0.80 earnings per share for the quarter, topping analysts' consensus estimates of $0.76 by $0.04. The firm earned $174.39 million during the quarter, compared to analyst estimates of $176.51 million. Lannett had a return on equity of 18.64% and a net margin of 7.01%. The business's quarterly revenue was up 7.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.77 earnings per share. View Lannett's Earnings History. When is Lannett's next earnings date? Lannett is scheduled to release their next quarterly earnings announcement on Wednesday, August, 22nd 2018. View Earnings Estimates for Lannett. What price target have analysts set for LCI? 5 equities research analysts have issued twelve-month price objectives for Lannett's shares. Their predictions range from $19.00 to $25.00. On average, they anticipate Lannett's stock price to reach $21.50 in the next year. This suggests a possible upside of 63.5% from the stock's current price. View Analyst Ratings for Lannett. What is the consensus analysts' recommendation for Lannett? 5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lannett in the last year. There are currently 4 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." Who are some of Lannett's key competitors? Some companies that are related to Lannett include Puma Biotechnology (PBYI), Myokardia (MYOK), Prestige Brands (PBH), Phibro Animal Health (PAHC), Insmed (INSM), Cambrex (CBM), Mallinckrodt (MNK), Aimmune Therapeutics (AIMT), PTC Therapeutics (PTCT), AnaptysBio (ANAB), Corcept Therapeutics (CORT), IMMURON Ltd/S (IMRN), Biohaven Pharmaceutical (BHVN), ARMO Biosciences (ARMO) and Innoviva (INVA). Who are Lannett's key executives? Lannett's management team includes the folowing people: Mr. Martin P. Galvan CPA, VP of Fin., CFO & Treasurer (Age 66)Mr. Robert Ehlinger, VP of Logistics & Chief Information Officer (Age 61)Mr. Kevin R. Smith, Sr. VP of Sales & Marketing (Age 58)Mr. John M. Abt, VP of Quality (Age 53)Mr. Arthur P. Bedrosian, Director (Age 72) Has Lannett been receiving favorable news coverage? News stories about LCI stock have trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Lannett earned a media sentiment score of 0.08 on Accern's scale. They also assigned news stories about the company an impact score of 45.35 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near future. Who are Lannett's major shareholders? Lannett's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Bank of Montreal Can (0.03%). Company insiders that own Lannett stock include Arthur P Bedrosian, David Farber, G Michael Landis, James M Maher, Kevin Smith, Patrick G Lepore and Timothy C Crew. View Institutional Ownership Trends for Lannett. Which major investors are buying Lannett stock? LCI stock was acquired by a variety of institutional investors in the last quarter, including Bank of Montreal Can. Company insiders that have bought Lannett stock in the last two years include Arthur P Bedrosian, Patrick G Lepore and Timothy C Crew. View Insider Buying and Selling for Lannett. How do I buy shares of Lannett? Shares of LCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Lannett's stock price today? One share of LCI stock can currently be purchased for approximately $13.15. How big of a company is Lannett? Lannett has a market capitalization of $516.99 million and generates $633.34 million in revenue each year. The company earns $-580,000.00 in net income (profit) each year or $2.86 on an earnings per share basis. Lannett employs 1,126 workers across the globe. How can I contact Lannett? Lannett's mailing address is 9000 STATE ROAD, PHILADELPHIA PA, 19136. The company can be reached via phone at 215-333-9000. MarketBeat Community Rating for Lannett (NYSE LCI)Community Ranking: 2.8 out of 5 ( )Outperform Votes: 362 (Vote Outperform)Underperform Votes: 278 (Vote Underperform)Total Votes: 640MarketBeat's community ratings are surveys of what our community members think about Lannett and other stocks. Vote "Outperform" if you believe LCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe LCI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 7/18/2018 by MarketBeat.com StaffFeatured Article: What are CEFs?